Crossmark

MetabOCT: a clinical trial looking for a metabolomic signature predicting the onset of Leber’s hereditary optic neuropathy in healthy MtDNA mutations carriers

Crossref DOI link: https://doi.org/10.1007/s11306-025-02328-x

Published Online: 2025-09-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Orssaud, Christophe https://orcid.org/0000-0003-2585-2114
Reynier, Pascal
Funding

Funding for this research was provided by:

Université d'Angers
License Information

Text and Data Mining valid from 2025-09-09

Version of Record valid from 2025-09-09
More Information

Article History

Received: 5 December 2024

Accepted: 29 July 2025

First Online: 9 September 2025

Declarations

:

: CO participated in an advisory board in April 2025 and led a workshop at the French Society of Ophthalmology in May 2025 on LHON funded by Chiesi. PR had none.

: All procedures performed in studies involving human participants will be in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent will be obtained from all participants included in the study.

Document is current

Any future updates will be listed below